Clinical trials: Kerato Conjunctivitis Sicca
Ocular Inflammation, Keratoconjunctivitis
Tolerability Comparison of Flarex to Lotemax SM
This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects.
- Conditions
- Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications
- Trial name
- NCT07588074
- Testing
- Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Harrow Inc
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.
- Trial name
- NCT01027013
- Testing
- rebamipide 2% ophthalmic suspension
- Where
- 5 sites in United States
- Volunteers
- 220 people
- Sponsor
- Kubota Vision Inc.
Dry Eye Syndromes
Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
- Trial name
- NCT03821415
- Testing
- RP101
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 104 people
- Sponsor
- Redwood Pharma AB
Dry Eye Disease
Evaluation of the Safety and Tolerability of Ocular Lubricants
The purpose of this study is to evaluate the safety and tolerability of three new artificial tear formulations in subjects with moderate dry eye disease.
- Trial name
- NCT06571656
- Testing
- FID123359 test formulation, FID123360 test formulation, FID123361 test formulation
- Where
- 5 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT01382225
- Testing
- Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle
- Volunteers
- 1,936 people
- Sponsor
- Alcon Research
Sjogren Disease
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
- Trial name
- EnVISage (NCT06928142)
- Testing
- Sibeprenlimab
- Where
- 64 sites in United States, Argentina and 6 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Keratoconjunctivitis Sicca
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine…
- Trial name
- NCT01817582
- Testing
- Lotemax, Restasis, Soothe® Lubricant Eye Drops
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.
- Trial name
- DROPS (NCT01900249)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 20 sites in United States
- Volunteers
- 204 people
- Sponsor
- Rigel Pharmaceuticals
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Dry Eye Disease
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) on ocular surface characteristics of subjects with dry eye disease (DED).
- Trial name
- NCT06544694
- Testing
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease
Effect of Cequa™ in Subjects With Dry Eye Disease
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
- Trial name
- NCT04357795
- Testing
- CequaTM (Cyclosporine 0.09%) ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Kerato Conjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With DED
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 3 (NCT03616899)
- Testing
- KPI-121 Ophthalmic Suspension, Vehicle
- Where
- 81 sites in United States
- Volunteers
- 901 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease, Kerato Conjunctivitis Sicca
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye…
- Trial name
- NCT05119920
- Testing
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3
- Where
- 19 sites in United States
- Volunteers
- 226 people
- Sponsor
- Glaukos Corporation
Keratoconjunctivitis Sicca, Dry Eye
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
- Trial name
- NCT01057147
- Testing
- rebamipide 2% ophthalmic suspension
- Where
- 19 sites in United States
- Volunteers
- 116 people
- Sponsor
- Kubota Vision Inc.
Dry Eye Syndrome
Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients
The study will assess the safety, tolerability and feasibility of Lacrima investigational medical device to treat dry eye patients
- Trial name
- NCT01957670
- Testing
- Lacrima medical Prototypes
- Where
- Israel
- Sponsor
- Lacrima Medical LTD
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune…
- Conditions
- Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid
- Trial name
- NCT00025818
- Testing
- Ophthalmic Emulsion
- Where
- 17 sites in United States
- Volunteers
- 290 people
- Sponsor
- Allergan
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study
To evaluate the safety and efficacy of 1% Pro-ocular topical gel administered twice daily for 12 weeks in treatment of Dry Eye Disease
- Trial name
- NCT04884217
- Testing
- Pro-ocular™ Topical Gel
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- PharmaDax Inc.